stockrowPrestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
- Revenue
- +22.7%
- EPS
- −38.4%
- Free cash flow
- −38.2%
- Total debt
- +100.9%
Quarter to September 2026, against a year earlier
Follow PBH
Alert me
Prestige Consumer Healthcare Inc. (PBH) Free cash flow margin
Prestige Consumer Healthcare Inc.'s free cash flow margin over the twelve months to 30 September 2026 was 18.4%, down 4.3 percentage points from fiscal 2026 (22.6%). Over the past ten years it has ranged from 16.5% (fiscal 2017) to 23.0% (fiscal 2022); the current reading is higher than 92% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2026 | 22.6% | 1.26 |
| FY2025 | 21.4% | 0.11 |
| FY2024 | 21.3% | 1.59 |
| FY2023 | 19.7% | (3.35) |
| FY2022 | 23.0% | 0.41 |
| FY2021 | 22.6% | 1.59 |
| FY2020 | 21.0% | 2.71 |
| FY2019 | 18.3% | (0.66) |
| FY2018 | 19.0% | 2.45 |
| FY2017 | 16.5% | (4.94) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | 38.1% |
| TRLV Trulieve Cannabis Corp. compare | 22.4% |
| XERS Xeris Biopharma Holdings, Inc. compare | 20.0% |
| PBH Prestige Consumer Healthcare Inc. | 18.4% |
| PRGO Perrigo Company plc compare | 4.11% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 0.00% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| ALVO Alvotech compare | 0.00% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on PBH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement